Background: In experimental models of cerebral ischemia, thrombolytic drugs have been demonstrated to have a number of neurovascular toxic effects including blood brain barrier disruption. Early barrier opening caused by focal cerebral ischemia in human stroke can be assessed by the presence of gadolinium enhancement of cerebrospinal fluid, termed ‘Hyperintense Acute Injury Marker’ (HARM). Methods: In a retrospective analysis, the frequency of HARM was studied in 140 patients, 38 receiving intra-arterial thrombolytics, 18 undergoing mechanical embolectomy, 24 receiving intravenous tissue plasminogen activator and 60 patients receiving no acute intervention. Results: HARM was found in 66% of patients undergoing intra-arterial thrombolysis and 50% of patients receiving intravenous tissue plasminogen activator, compared to 28% of patients undergoing mechanical embolectomy and 30% of patients receiving no acute therapy (p = 0.002). Both thrombolytic therapy (p = 0.001) and age (p = 0.001) were independent predictors of HARM. HARM was an independent predictor of hemorrhagic transformation (p = 0.007). Conclusions: This is the first study in humans providing supportive evidence of the neurovascular toxic effects of thrombolytics and suggests that HARM may be used as a biomarker of blood brain barrier disruption in future research of acute stroke therapies.

Keywords:
Ischemic stroke, Thrombolysis, Blood brain barrier, Mechanical embolectomy, MRI
1.
NINDS rt-PA Stroke Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
2.
Furlan A, Higashida R, Wechsler L, et al: Intra-arterial prourokinase for acute ischemic stroke – The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–2011.
3.
Smith WS, Sung G, Starkman S, et al: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI Trial. Stroke 2005;36:1432–1438.
4.
Latour LL, Kang DW, Ezzeddine MA, et al: Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004;56:468–477.
5.
Dechambre SD, Duprez T, Grandin CB, et al: High signal in cerebrospinal fluid mimicking subarachnoid haemorrhage on FLAIR following acute stroke and intravenous contrast medium. Neuroradiology 2000;42:608–611.
6.
TIMI Study Group: The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. New Engl J Med 1985;312:932–936.
7.
Kidwell CS, Saver JL, Carneado J, et al: Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717–724.
8.
Adams HP Jr, Adams RJ, Brott T, et al: Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056–1083.
9.
Wang X, Tsuji K, Lee SR, et al: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35:2726–2730.
10.
Del Zoppo GJ: tPA: a neuron buster, too? Nat Med 1998;4:148–150.
11.
Kaur J, Zhao Z, Klein GM, et al: The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004;24:945–963.
12.
Tsirka SE, Gualandris A, Amaral DG, Strickland S: Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340–344.
13.
Tsirka SE, Rogove AD, Strickland S: Neuronal cell death and tPA. Nature 1996;384:123–124.
14.
Wang YF, Tsirka SE, Strickland S, et al: Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998;4:228–231.
15.
Nicole O, Docagne F, Ali C, et al: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59–64.
16.
Liu D, Cheng T, Guo H, et al: Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004;10:1379–1383.
17.
Sumii T, Lo EH: Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831–836.
18.
Wang X, Lee SR, Arai K, et al: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003;9:1313–1317.
19.
Yepes M, Sandkvist M, Moore EG, et al: Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003;112:1533–1540.
20.
Pfefferkorn T, Rosenberg GA: Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003;34:2025–2030.
21.
Jiang Q, Ewing JR, Ding GL, et al: Quantitative evaluation of BBB permeability after embolic stroke in rat using MRI. J Cereb Blood Flow Metab 2005;25:583–592.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.